Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPI-145 versus Ofatumumab in Relapsed or Refractory CLL/SLL
2013-002405-61Phase 3Active
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of duvelisib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Infinity Pharmaceuticals, Inc. Primary endpoint: Progression-free survival. Started Dec 2013; status: active.
02
Drugs
duvelisib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2013-002405-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002405-61.